Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.
Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.
Oxnard says the standard of care is chemotherapy with pemetrexed and platinum based on the IMPRESS trial, which showed a response rate of 32% and a profession-free survival rate (PFS) of 5 to 6 months. He adds that other options for patients are now available, such as afatinib which has a response rate of around 10% and a PFS of about 3 months.
Oxnard also says emerging EGFR inhibitors such as rociletinib and osimertinib could be options for patients as well, depending on the situation.
Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma
May 19th 2025In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.
Read More